Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2849903 | American Heart Journal | 2015 | 9 Pages |
Abstract
Utilization of drug combinations to treat cardiovascular conditions does not correspond well with availability of FDCs containing these agents. A concerted set of strategies should be implemented to streamline the development of useful combination products, including expedited approval pathways and increased investment in formulation studies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Bo PharmD, Niteesh K. MD, PhD, Joshua J. PharmD, ScD, Joan MPH, Aaron S. MD, JD, MPH,